GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.

Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell therapy for the treatment of Hepatocellular Carcinoma (HCC) after curative resection and has received FDA Orphan Drug Designations (ODDs) for liver, brain, and pancreatic cancers.
Immuncell-LC Inj. reduced HCC recurrence by 37% mortality by 79% in its Phase 3 study. (Link)
Through this agreement with BioCentriq, GC Cell is accelerating the transfer of Immuncell-LC Inj. into the North American market in response to the significant attention it has garnered from leading US pharma and biotech companies with whom GC Cell is actively pursuing potential collaboration discussions.

YONGIN, South Korea and NEWARK, N.J., Feb. 26, 2024 /PRNewswire/ — GC Cell, a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq, a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell. This important partnership lays the foundation to bring GC Cells’ proven cell-based immunotherapy, Immuncell-LC to the North American market. The execution of a Process Transfer Agreement with BioCentriq effectively lays the foundation for the U.S. launch of Immuncell-LC through utilization of BioCentriq’s cell therapy process development, analytical method development and manufacturing expertise.

Full story available on Benzinga.com